Quantum Genomics Société Anonyme Valuation
Is ALQGC undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ALQGC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ALQGC's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ALQGC's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALQGC?
Key metric: As ALQGC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is ALQGC's PB Ratio? | |
|---|---|
| PB Ratio | -2.8x |
| Book | -€1.78m |
| Market Cap | €5.03m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 352573.6x |
| Enterprise Value/EBITDA | -3.3x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does ALQGC's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 2.3x | ||
ALTME TME Pharma | 4.1x | n/a | €6.5m |
ALNOV Novacyt | 0.5x | n/a | €40.7m |
ALVIO Valerio Therapeutics Société anonyme | 2.8x | n/a | €11.4m |
ALINT IntegraGen | 1.6x | n/a | €3.0m |
ALQGC Quantum Genomics Société Anonyme | n/a | n/a | €5.0m |
Price-To-Book vs Peers: ALQGC has negative equity and a Price-To-Book Ratio (-2.8x) compared to the peer average (2.3x).
Price to Book Ratio vs Industry
How does ALQGC's PB Ratio compare vs other companies in the FR Biotechs Industry?
Price-To-Book vs Industry: ALQGC has negative equity and a Price-To-Book Ratio (-2.8x) compared to the French Biotechs industry average (1.9x).
Price to Book Ratio vs Fair Ratio
What is ALQGC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | -2.8x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate ALQGC's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Virbac
€2.7b
Manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East.
VIRP
€328.50
7D
2.8%
1Y
14.7%
Sanofi
€116.3b
A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.
SAN
€91.72
7D
0.6%
1Y
6.9%
Eurofins Scientific
€9.0b
Provides various analytical testing and laboratory services worldwide.
ERF
€46.32
7D
1.8%
1Y
-12.0%